Trial · NCT04703075
Ultra Curto (Ultra Short) TB Prevention Therapy
NCT04703075, Phase 4, Completed, Johns Hopkins University; results first posted 2025-06-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ultra Curto (Ultra Short) TB Prevention Therapy. Trials, record NCT04703075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04703075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ultra Curto (Ultra Short) TB Prevention Therapy
- NCT number
- NCT04703075
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 531 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Tuberculosis
- Interventions
- Rifapentine 600 mg and INH 300 mg, Rifapentine 900 mg and INH 900 mg
- First posted
- 2021-01-11
- Last updated
- 2025-06-19
- Results first posted
- 2025-06-19
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Complete Treatment With >90% Adherence | 6 months | To compare treatment success (completion of treatment with \>90% adherence) of 1HP with 3HP in HIV-uninfected adults and adolescents at increased risk of TB. |
| Primary | Frequency of Targeted Adverse Events or Treatment Discontinuation for Side Effects | 6 months | Participants with targeted adverse event grade 2 or more or discontinuing treatment for any side effect. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Complete Treatment With >90% Adherence | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Frequency of Targeted Adverse Events or Treatment Discontinuation for Side Effects | 6 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Complete Treatment With >90% Adherence | Arm A: 1HP | 223 | Participants | ||
| Number of Participants Who Complete Treatment With >90% Adherence | Arm B: 3HP | 211 | Participants | ||
| Frequency of Targeted Adverse Events or Treatment Discontinuation for Side Effects | Arm A: 1HP | 40 | Participants | ||
| Frequency of Targeted Adverse Events or Treatment Discontinuation for Side Effects | Arm B: 3HP | 26 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: 1HP | 249 | |
| Overall Study | STARTED | Arm B: 3HP | 251 | |
| Overall Study | COMPLETED | Arm A: 1HP | 223 | |
| Overall Study | COMPLETED | Arm B: 3HP | 211 | |
| Overall Study | NOT COMPLETED | Arm A: 1HP | 26 | |
| Overall Study | NOT COMPLETED | Arm B: 3HP | 40 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hepatotoxicity | Hepatobiliary disorders | Arm A: 1HP | 13 | 249 | 13 |
| other | Hepatotoxicity | Hepatobiliary disorders | Arm B: 3HP | 10 | 251 | 10 |
| serious | Hospitalization | Surgical and medical procedures | Arm A: 1HP | 1 | 249 | 1 |
| serious | Hospitalization | Surgical and medical procedures | Arm B: 3HP | 2 | 251 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: 1HP | 0 | 249 |
| Total, all-cause mortality | Arm B: 3HP | 0 | 251 |
| Total, other adverse events | Arm A: 1HP | 13 | 249 |
| Total, other adverse events | Arm B: 3HP | 10 | 251 |
| Total, serious adverse events | Arm A: 1HP | 1 | 249 |
| Total, serious adverse events | Arm B: 3HP | 2 | 251 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41666121 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01AI152961 | Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals | CHAISSON, RICHARD E. | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2020 to 2024 |
Source NIH RePORTER
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm A: 1HP vs Arm B: 3HP: Number of Participants Who Complete Treatment With >90% Adherence | Trial comparisons |
| Arm A: 1HP vs Arm B: 3HP: deaths from any cause | Trial comparisons |
| Arm A: 1HP vs Arm B: 3HP: Frequency of Targeted Adverse Events or Treatment Discontinuation for Side Effects | Trial comparisons |
| Arm A: 1HP vs Arm B: 3HP: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04703075
GET https://conductscience.org/api/trials/v1/NCT04703075/registered